Development and external validation of a pathological nodal staging score for patients with clear cell renal cell carcinoma

Malte Rieken, Stephen A. Boorjian, Luis A. Kluth, Umberto Capitanio, Alberto Briganti, R. Houston Thompson, Bradley Leibovich, Laura Maria Krabbe, Vitaly Margulis, Jay D. Raman, Mikhail Regelman, Pierre I. Karakiewicz, Morgan Rouprêt, Mohammad Abufaraj, Beat Foerster, Mithat Gönen, Shahrokh F. Shariat

Research output: Contribution to journalArticle

Abstract

Objectives: To develop and externally validate a model that quantifies the likelihood that a pathologically node-negative patient with clear cell renal cell carcinoma (cRCC) has, indeed, no lymph node metastasis (LNM). Patients and methods: Data from 1389 patients treated with radical nephrectomy (RN) and lymph node dissection (LND) were analyzed. For external validation, we used data from 2270 patients in the Surveillance, Epidemiology and End Results (SEER) database. We estimated the sensitivity of pathologic nodal staging using a beta-binomial model and developed a pathological nodal staging score (pNSS), which represents the probability that a patient is correctly staged as node negative as a function of the number of examined lymph nodes (LNs). Results: The mean and median number of LNs removed were 7.0 and 5.0 (standard deviation, SD 6.6; interquartile range, IQR 7.0) in the development cohort and 5.6 and 2.0 (SD 8.6, IQR 5.0) in the validation cohort, respectively. The probability of missing a positive LN decreased with increasing number of LNs examined. In both the validation and the development cohort, the number of LNs needed for correctly staging a patient as node negative increased with higher pathological tumor stage and Fuhrman grade. Conclusions: The number of examined LNs needed for adequate nodal staging in cRCC depends on pathological tumor stage and Fuhrman grade. We developed here and then externally validated a pNSS, which could help to refine patient counseling, decision-making regarding risk-stratified surveillance regimens and inclusion criteria for clinical trials of adjuvant therapy.

Original languageEnglish (US)
Pages (from-to)1631-1637
Number of pages7
JournalWorld Journal of Urology
Volume37
Issue number8
DOIs
StatePublished - Aug 1 2019

Fingerprint

Renal Cell Carcinoma
Lymph Nodes
Statistical Models
Lymph Node Excision
Nephrectomy
Counseling
Neoplasms
Decision Making
Epidemiology
Clinical Trials
Databases
Neoplasm Metastasis

Keywords

  • Clear cell renal cell carcinoma
  • Lymph node dissection
  • Lymph node metastasis
  • Radical nephrectomy
  • SEER
  • Validation

ASJC Scopus subject areas

  • Urology

Cite this

Rieken, M., Boorjian, S. A., Kluth, L. A., Capitanio, U., Briganti, A., Thompson, R. H., ... Shariat, S. F. (2019). Development and external validation of a pathological nodal staging score for patients with clear cell renal cell carcinoma. World Journal of Urology, 37(8), 1631-1637. https://doi.org/10.1007/s00345-018-2555-5

Development and external validation of a pathological nodal staging score for patients with clear cell renal cell carcinoma. / Rieken, Malte; Boorjian, Stephen A.; Kluth, Luis A.; Capitanio, Umberto; Briganti, Alberto; Thompson, R. Houston; Leibovich, Bradley; Krabbe, Laura Maria; Margulis, Vitaly; Raman, Jay D.; Regelman, Mikhail; Karakiewicz, Pierre I.; Rouprêt, Morgan; Abufaraj, Mohammad; Foerster, Beat; Gönen, Mithat; Shariat, Shahrokh F.

In: World Journal of Urology, Vol. 37, No. 8, 01.08.2019, p. 1631-1637.

Research output: Contribution to journalArticle

Rieken, M, Boorjian, SA, Kluth, LA, Capitanio, U, Briganti, A, Thompson, RH, Leibovich, B, Krabbe, LM, Margulis, V, Raman, JD, Regelman, M, Karakiewicz, PI, Rouprêt, M, Abufaraj, M, Foerster, B, Gönen, M & Shariat, SF 2019, 'Development and external validation of a pathological nodal staging score for patients with clear cell renal cell carcinoma', World Journal of Urology, vol. 37, no. 8, pp. 1631-1637. https://doi.org/10.1007/s00345-018-2555-5
Rieken, Malte ; Boorjian, Stephen A. ; Kluth, Luis A. ; Capitanio, Umberto ; Briganti, Alberto ; Thompson, R. Houston ; Leibovich, Bradley ; Krabbe, Laura Maria ; Margulis, Vitaly ; Raman, Jay D. ; Regelman, Mikhail ; Karakiewicz, Pierre I. ; Rouprêt, Morgan ; Abufaraj, Mohammad ; Foerster, Beat ; Gönen, Mithat ; Shariat, Shahrokh F. / Development and external validation of a pathological nodal staging score for patients with clear cell renal cell carcinoma. In: World Journal of Urology. 2019 ; Vol. 37, No. 8. pp. 1631-1637.
@article{daeaacec70284a9abd93758f243109fe,
title = "Development and external validation of a pathological nodal staging score for patients with clear cell renal cell carcinoma",
abstract = "Objectives: To develop and externally validate a model that quantifies the likelihood that a pathologically node-negative patient with clear cell renal cell carcinoma (cRCC) has, indeed, no lymph node metastasis (LNM). Patients and methods: Data from 1389 patients treated with radical nephrectomy (RN) and lymph node dissection (LND) were analyzed. For external validation, we used data from 2270 patients in the Surveillance, Epidemiology and End Results (SEER) database. We estimated the sensitivity of pathologic nodal staging using a beta-binomial model and developed a pathological nodal staging score (pNSS), which represents the probability that a patient is correctly staged as node negative as a function of the number of examined lymph nodes (LNs). Results: The mean and median number of LNs removed were 7.0 and 5.0 (standard deviation, SD 6.6; interquartile range, IQR 7.0) in the development cohort and 5.6 and 2.0 (SD 8.6, IQR 5.0) in the validation cohort, respectively. The probability of missing a positive LN decreased with increasing number of LNs examined. In both the validation and the development cohort, the number of LNs needed for correctly staging a patient as node negative increased with higher pathological tumor stage and Fuhrman grade. Conclusions: The number of examined LNs needed for adequate nodal staging in cRCC depends on pathological tumor stage and Fuhrman grade. We developed here and then externally validated a pNSS, which could help to refine patient counseling, decision-making regarding risk-stratified surveillance regimens and inclusion criteria for clinical trials of adjuvant therapy.",
keywords = "Clear cell renal cell carcinoma, Lymph node dissection, Lymph node metastasis, Radical nephrectomy, SEER, Validation",
author = "Malte Rieken and Boorjian, {Stephen A.} and Kluth, {Luis A.} and Umberto Capitanio and Alberto Briganti and Thompson, {R. Houston} and Bradley Leibovich and Krabbe, {Laura Maria} and Vitaly Margulis and Raman, {Jay D.} and Mikhail Regelman and Karakiewicz, {Pierre I.} and Morgan Roupr{\^e}t and Mohammad Abufaraj and Beat Foerster and Mithat G{\"o}nen and Shariat, {Shahrokh F.}",
year = "2019",
month = "8",
day = "1",
doi = "10.1007/s00345-018-2555-5",
language = "English (US)",
volume = "37",
pages = "1631--1637",
journal = "World Journal of Urology",
issn = "0724-4983",
publisher = "Springer Verlag",
number = "8",

}

TY - JOUR

T1 - Development and external validation of a pathological nodal staging score for patients with clear cell renal cell carcinoma

AU - Rieken, Malte

AU - Boorjian, Stephen A.

AU - Kluth, Luis A.

AU - Capitanio, Umberto

AU - Briganti, Alberto

AU - Thompson, R. Houston

AU - Leibovich, Bradley

AU - Krabbe, Laura Maria

AU - Margulis, Vitaly

AU - Raman, Jay D.

AU - Regelman, Mikhail

AU - Karakiewicz, Pierre I.

AU - Rouprêt, Morgan

AU - Abufaraj, Mohammad

AU - Foerster, Beat

AU - Gönen, Mithat

AU - Shariat, Shahrokh F.

PY - 2019/8/1

Y1 - 2019/8/1

N2 - Objectives: To develop and externally validate a model that quantifies the likelihood that a pathologically node-negative patient with clear cell renal cell carcinoma (cRCC) has, indeed, no lymph node metastasis (LNM). Patients and methods: Data from 1389 patients treated with radical nephrectomy (RN) and lymph node dissection (LND) were analyzed. For external validation, we used data from 2270 patients in the Surveillance, Epidemiology and End Results (SEER) database. We estimated the sensitivity of pathologic nodal staging using a beta-binomial model and developed a pathological nodal staging score (pNSS), which represents the probability that a patient is correctly staged as node negative as a function of the number of examined lymph nodes (LNs). Results: The mean and median number of LNs removed were 7.0 and 5.0 (standard deviation, SD 6.6; interquartile range, IQR 7.0) in the development cohort and 5.6 and 2.0 (SD 8.6, IQR 5.0) in the validation cohort, respectively. The probability of missing a positive LN decreased with increasing number of LNs examined. In both the validation and the development cohort, the number of LNs needed for correctly staging a patient as node negative increased with higher pathological tumor stage and Fuhrman grade. Conclusions: The number of examined LNs needed for adequate nodal staging in cRCC depends on pathological tumor stage and Fuhrman grade. We developed here and then externally validated a pNSS, which could help to refine patient counseling, decision-making regarding risk-stratified surveillance regimens and inclusion criteria for clinical trials of adjuvant therapy.

AB - Objectives: To develop and externally validate a model that quantifies the likelihood that a pathologically node-negative patient with clear cell renal cell carcinoma (cRCC) has, indeed, no lymph node metastasis (LNM). Patients and methods: Data from 1389 patients treated with radical nephrectomy (RN) and lymph node dissection (LND) were analyzed. For external validation, we used data from 2270 patients in the Surveillance, Epidemiology and End Results (SEER) database. We estimated the sensitivity of pathologic nodal staging using a beta-binomial model and developed a pathological nodal staging score (pNSS), which represents the probability that a patient is correctly staged as node negative as a function of the number of examined lymph nodes (LNs). Results: The mean and median number of LNs removed were 7.0 and 5.0 (standard deviation, SD 6.6; interquartile range, IQR 7.0) in the development cohort and 5.6 and 2.0 (SD 8.6, IQR 5.0) in the validation cohort, respectively. The probability of missing a positive LN decreased with increasing number of LNs examined. In both the validation and the development cohort, the number of LNs needed for correctly staging a patient as node negative increased with higher pathological tumor stage and Fuhrman grade. Conclusions: The number of examined LNs needed for adequate nodal staging in cRCC depends on pathological tumor stage and Fuhrman grade. We developed here and then externally validated a pNSS, which could help to refine patient counseling, decision-making regarding risk-stratified surveillance regimens and inclusion criteria for clinical trials of adjuvant therapy.

KW - Clear cell renal cell carcinoma

KW - Lymph node dissection

KW - Lymph node metastasis

KW - Radical nephrectomy

KW - SEER

KW - Validation

UR - http://www.scopus.com/inward/record.url?scp=85056278204&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056278204&partnerID=8YFLogxK

U2 - 10.1007/s00345-018-2555-5

DO - 10.1007/s00345-018-2555-5

M3 - Article

C2 - 30406477

AN - SCOPUS:85056278204

VL - 37

SP - 1631

EP - 1637

JO - World Journal of Urology

JF - World Journal of Urology

SN - 0724-4983

IS - 8

ER -